• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Patent On AIDS Drug Will Not Limit Access In India, Industry Argues

30/03/2006 by Tove Iren S. Gerhardsen for Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

It is “misleading” and “counter-productive” to assert that a pharmaceutical company’s filing for a patent on a HIV/AIDS drug in India will limit access to the drug in the future, GlaxoSmithKline said in response to an objection submitted today in India.

The comment is a response to the submission of a “pre-grant opposition” to the patent filing in India, staged by the Indian Network for People Living with HIV/AIDS, the Manipur Network of Positive People, and the Lawyers’ Collective HIV/AIDS Unit, reported on by Intellectual Property Watch (IPW, Public Health, 30 March 2006).

The networks protested against GSK’s patent application for its fixed-dose combination of two AIDS drugs, zidovudine/lamivudine or AZT/3TC (Combivir). This is the first application filed in India for an HIV/AIDS medicine since India introduced patents on pharmaceuticals in 2005.

The drug is currently available in copy, or generic, form in India, but the networks are concerned that a future patent would boost the price of the drug and make it difficult for other companies to start producing the drug, thus affecting access. They argue that the product is merely a combination of two existing drugs and thus does not qualify as an innovation.

A GlaxoSmithKline spokesperson told Intellectual Property Watch that the patent “would not affect the cost or availability of generic versions already available in India.” GSK argues that the 2005 patent law that brought India into line with World Trade Organization rules contains provisions on flexibilities such as compulsory licenses to address public health concerns. These flexibilities would meet concerns in India as well as abroad in terms of export, the spokesperson said.

“It is misleading and counter-productive to focus on patents or full implementation of patent protection as a significant barrier to access to medicines in India and beyond,” the spokesperson said. She said that 98 percent of the drugs on the World Health Organization (WHO) Essential Drugs List are not patent-protected, but still two-thirds of the world’s population does not have access to them, according to WHO estimates.

“The root cause of developing countries’ inability to address their healthcare problems does not lie with the patenting system but with a lack of funding, a lack of political will and inadequate healthcare infrastructure,” the spokesperson said.

The spokesperson added that GSK makes Combivir available at not-for-profit prices in the poorest countries in the world and “shipped 126 million preferentially prices Combivir/Epivir tablets to the developing world” in 2005. The company also has granted seven voluntary licenses to generics manufacturers for the sale of antiretrovirals (HIV/AIDS medicines) in sub-Saharan Africa, she said.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Patent On AIDS Drug Will Not Limit Access In India, Industry Argues" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: News, Venues, Asia/Pacific, English, Health & IP, Patents/Designs/Trade Secrets, Regional Policy, WHO

Comments

  1. James Love says

    30/03/2006 at 8:55 pm

    I don’t know why anyone would believe this assertion. There is plently of evidence that GSK has sought the hightest prices it could, and prices have only actually fallen in cases where the exists competition. The patent will degeree competition, and make it much more complicated to export, under the 30 August 03 proceedures.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2019 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.